Cleerly Inc. sees a bright future ahead after boosting its fundraising to date nearly five-fold with a $192 million series C. The new infusion brought the total invested in the company to $248 million, a solid endorsement of a company that hopes to transform cardiology with precision-based diagnostics that move away from indirect indicators to accurate measurements.
Calyxo Inc. cleaned up with a $32.7 million series C financing round to support further development of the Cvac system for kidney stones. Questa Capital and CRG led the round, which brought the company’s total funds raised to $47.2 million.
Megarobo Technologies Ltd. raised $300 million in its series C round financing to develop intelligence and automation solutions for life science companies. The financing was led by Goldman Sachs Asset Management LP, Asia Investment Capital Ltd., and GGV Capital.
Diabeloop SA has just closed a series C funding round, securing $73 million to ramp global expansion for its DBL1 integrated smart system for patients with type 1 diabetes. “This will allow us to boost commercial roll-out and continue pursuing our growth strategy into Europe, the U.S. and Asia,” Erik Huneker, CEO of Diabeloop, told BioWorld.
Imcheck Therapeutics SAS raised €80 million (US $83.5 million) in a series C round to maintain the momentum of its lead development program, ICT-01, an immunostimulatory antibody that activates gamma-delta T cells.
Kriya Therapeutics Inc. has raised a $270 million series C financing to further develop its pipeline of gene therapies for treating cancer, ophthalmological problems, and rare and chronic diseases. The Redwood City, Calif.-based company has greatly expanded its employee roster, from about seven people to around 160 people, since its $80 million series A in May 2020 and scaled its learning-enabled tech and cloud computing abilities. It also further solidified its technology, manufacturing, R&D, and therapeutics units, something it plans to continue with the series C money.
The short-term future is a little clearer for Israeli precision oncology startup Oncohost Ltd. now that it has closed a $35 million series C fundraising round. The new infusion more than doubled the previous amount raised, bringing total investment to more than $50 million. The company plans to use the funds to expand its PROPHETIC trial of the company’s machine learning-based host response profiling platform, Prophet, to additional locations worldwide and new indications.
3Spine Inc. has raised $33 million in an oversubscribed series C private offering for a phase II clinical study to assess what it calls “the first total joint replacement” for the lower back. This brings total private investment in the Balancedback total joint replacement to $50.3 million, largely due, said 3Spine CEO Marc Peterman, to “tremendous clinical outcomes and a mountain of benchtop research.”
RSS
